{
  "ticker": "LLY",
  "target_date": "2025-03-20",
  "actual_date": "2025-03-20",
  "collected_at": "2025-12-08T11:32:33.511148",
  "price": {
    "open": 834.25,
    "high": 849.53,
    "low": 827.72,
    "close": 837.7733764648438,
    "volume": 4402700,
    "change_1d_pct": 0.66,
    "change_7d_pct": 2.25,
    "change_30d_pct": 0.22
  },
  "technicals": {
    "rsi_14": 32.25,
    "sma_20": 863.47,
    "sma_50": 829.5,
    "macd": -6.714,
    "macd_signal": 0.542,
    "macd_histogram": -7.255,
    "bb_upper": 951.97,
    "bb_lower": 774.96,
    "price_vs_sma20_pct": -2.98,
    "price_vs_sma50_pct": 1.0,
    "volume_ratio": 1.2
  },
  "fundamentals": {
    "market_cap": 889069961216,
    "pe_ratio": 48.59187,
    "forward_pe": 43.76699,
    "price_to_book": 37.340363,
    "price_to_sales": 14.962521,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.81,
    "pct_from_52w_low": 58.99
  },
  "macro": {
    "spy": {
      "price": 560.58,
      "change_1d_pct": -0.29,
      "change_7d_pct": 1.18
    },
    "vix": {
      "level": 19.8,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.23
    },
    "dollar_index": {
      "level": 103.85
    },
    "gold": {
      "price": 3040.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "BlackRock Tactical Opportunities Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1742508780,
      "summary": "BlackRock Tactical Opportunities Fund posted Q4 2024 returns of 4.65% (Institutional shares) and 4.58% (Investor A shares, without sales charge), while BofA ML 3-Month T-Bill returned 1.17%.",
      "url": "https://finnhub.io/api/news?id=48c57fbb2e8ef464f3bf00611efed384dca5d8c93e7edb9650bc211c8eb94fd2"
    },
    {
      "headline": "Tracking Philippe Laffont's Coatue Management Portfolio - Q4 2024 Update",
      "source": "SeekingAlpha",
      "datetime": 1742500905,
      "summary": "Coatue Management's 13F portfolio increased from $26.92B to $29.68B. Read here for latest updates like new stakes, top holdings, and major changes in tech giants.",
      "url": "https://finnhub.io/api/news?id=6d8832482796059cc517c0cf653abbd3075425615bd6e0e849beddef24fd9037"
    },
    {
      "headline": "Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market",
      "source": "Yahoo",
      "datetime": 1742486795,
      "summary": "Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug: NOVO NORDISK The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ingredient in Wegovy is semaglutide, whic",
      "url": "https://finnhub.io/api/news?id=9466d589db9a274fda91392a450c2d55ed16bfc4095160942ccfe6d0fa8fa8d1"
    },
    {
      "headline": "3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets",
      "source": "SeekingAlpha",
      "datetime": 1742475790,
      "summary": "Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.",
      "url": "https://finnhub.io/api/news?id=18230ff58e9aced29e03768ed7243a564c5bfe4a848f02601a418129b3decaba"
    },
    {
      "headline": "Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market",
      "source": "Finnhub",
      "datetime": 1742472521,
      "summary": "India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo...",
      "url": "https://finnhub.io/api/news?id=7940ba48c816bad3e6b4ba9b6dc2ae6cae53d04dbb1c3362459883cf64331bf9"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}